Text
Efficacy and Safety of Adapalene 0.1% Cream in the Tratment of Skin Photoaging
This was a comparative, 2-arm, parallel, randomized, double-blind, placebo-controlled study consisting of a 12-week treatment period aimed to evaluate the efficacy and safety of topical adapa-lene 0.1% cream as an anti-aging therapy. Each enrolled subjects were given both adapalene and place¬bo (vehicle) cream, each of which to be applied on either hand based on the randomly allocated num¬ber. Subjects were instructed to apply the study medication once daily in the evening on the back of each hand and let the medication get contacted with the skin for approximately 8 hours daily. Moisturizers and other topical medications were not allowed during the study. A sunscreen with an SPF of 30 was provided to each study subject to be used daily. Changes of colorimetric (melanin value) and profilometric (skin roughness and wrinkles) indices from baseline to the end of treatment were evaluated as the primary efficacy endpoints. Secondary efficacy endpoints were clil:Jical improvement of photoaging, Physician's Global Evaluation as well as Subject self-evaluation on clinical response, Forty subjects of 52.6 :t 5.5 years of age, of female (80%) and skin photo-type IV (95%) predominance were enrolled in the study. Baseline conditions were comparable between groups (hands). In this study, ada-palene O. 1 % cream has not yet showed a significantly better improvement in terms of colorimetric and profilometric indices, as compared to placebo. However, adapalene still demonstrated a more favorable clinical improvement than the placebo, indicating that adapalene reverses some - yet not all - of the signs of photoaging. Adapalene was regarded as safe and tolerable. The study concluded that adapa¬lene 0.1% cream was clinically beneficial and tolerable for the treatment of skin photoaging.
No other version available